May 19, 2008 - PhytoPharmacon LLC (formerly SaviPu Pharmaceuticals), a privately owned biopharmaceutical company, announced today the issuance of a new patent. The issued patent covers Myriceric acid derivatives for the treatment of cancer, cardiovascular and inflammatory diseases. The company is currently developing a Myriceric Acid A analog for the treatment of Androgen Refractory Prostate Cancer, one of the therapeutic areas of focus for PhytoPharmacon.
The patent also includes pharmaceutical compositions, methods of treatment for a number of other important inflammatory and cardiovascular diseases particularly arthritis, inflammatory bowel disease, asthma and COPD, osteoporosis, Alzheimer's, stroke, atherosclerosis, restenosis, diabetes, glomerulonephritis, cancer and cachexia.
The details can be read here.
No comments:
Post a Comment